🇺🇸 SACITUZUMAB GOVITECAN in United States

3,167 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Disease Progression — 752 reports (23.74%)
  2. Death — 480 reports (15.16%)
  3. Inappropriate Schedule Of Product Administration — 345 reports (10.89%)
  4. Diarrhoea — 344 reports (10.86%)
  5. Neutropenia — 269 reports (8.49%)
  6. Off Label Use — 242 reports (7.64%)
  7. Fatigue — 199 reports (6.28%)
  8. Weight Fluctuation — 186 reports (5.87%)
  9. Asthenia — 181 reports (5.72%)
  10. Nausea — 169 reports (5.34%)

Source database →

SACITUZUMAB GOVITECAN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SACITUZUMAB GOVITECAN approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for SACITUZUMAB GOVITECAN in United States?

Marketing authorisation holder not available in our data.